This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Repros Worried About Validity of its Androxal Patent

Stocks in this article: RPRX

THE WOODLANDS, Tex. ( TheStreet) -- Repros Therapeutics (RPRX) CEO Joe Podolski likes to assure investors the company's testosterone-boosting pill Androxal is backed by strong patent protection. But Repros' action to affirm the Androxal patent in a Texas court suggests the company is actually much more worried than it lets on about the risk its Androxal patent is invalidated.

Monday, Repros said it filed an action in federal court, "seeking a declaratory judgment affirming Repros' intellectual property rights relating to its Androxal technology. This action is being taken to address issues alleged by a third party relating to the Repros issued patents claiming the use of the pure trans isomer of the drug clomiphene citrate."

That last sentence is key. That "third party" referred to by Repros is Dr. Harry Fisch, a New York urologist who accuses Podolski of stealing the idea for Androxal from him after a face-to-face meeting in New York City. Podolski denies Fisch's theft charge, but Repros began developing Androxal after the meeting between the two men.

Fisch has his own U.S. patent, awarded in 2001, covering the use of clomiphene to treat androgen testosterone deficiency in men. Repros' Androxal is an isomer of clomiphene. The company's U.S. patent covering Androxal was granted after Fisch's patent.

Monday's action by Repros appears to be the company playing defense, hoping a U.S. court will declare its Androxal patent valid. But why take this extra-ordinary legal action unless there was some real concern and risk that Repros' patent could be declared invalid?

Repros has long said it wants to license Androxal to a large drug company for commercial marketing, but again, Monday's action suggests the company is having trouble with partnering negotiations. It's likely most potential Big Pharma partners don't want to go anywhere near Androxal with the drug's patent protection in dispute.

Fisch might also respond to Repros' legal action by seeking to convince the court not to affirm the company's Androxal patent. Fisch could also go one step further and seek a court ruling declaring himself co-author of the Repros Androxal patent (on the grounds that the company stole his idea.)

In other words, Repros would have to establish Fisch as co-owner of the Androxal patent and all the economics that flow from it. Clearly, this would be a disastrous turn of events for Repros.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs